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Introduction 
  It is estimated that more than one fifth of world’s population lives in 
India.  Today, India is one of the fastest growing economies in the world. 
Urbanization is rapid as ever. Young and old abandoning healthy Indian lifestyle 
and culture for western culture in the name of modern living. Sedentary lifestyle, 
low fibre, high fat and energy rich foods have penetrated even the rural India in the 
name of globalization. All these will come not without cost. India is now facing 
paradox of malnutrition on one hand and epidemic of obesity on the other. 
 Indians three times higher risk of developing Coronary Artery Disease (CAD) 
compared to Chinese and are 20 times more likely to die due to CAD compared to 
native black or white South Africans. 1, 2 The SHARE study demonstrated that South 
Asians had higher prevalence of cardiovascular disease compared to Europeans and 
Chinese living in Canada.3 In India 2.78 million deaths are due to cardiovascular 
diseases, of which over 50% is due to CAD, making CAD the number one killer 
disease in our country.4 In Jaipur Heart Watch – 2 study conducted in 2002, 
prevalence of CAD was reported to be 8.2%.5 
 Over 35 million diabetic patients live in India, making India the diabetic 
capital in the world. These numbers expected to double by the year 2030.6 Thus India 
faces the dangerous dual epidemic of diabetes and CAD. The major root of both 
epidemics lies in “Metabolic Syndrome”.  
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Lots of studies from west on metabolic syndrome represent middle and 
higher socioeconomic classes of society. Those studies which assess the burden of 
metabolic syndrome in CAD patients living below poverty line in India is still 
lacking. Thus it is worthwhile effort to find out the burden of metabolic syndrome in 
less privileged poor CAD patients of Chennai city. Kilpauk Medical College Hospital 
is being a Government run institution serves these patients either free of cost or with 
minimal fee. Majority of patients attending the OPDs of the hospital are poor, hence 
giving good opportunity to study the problem pertaining to these patients. 
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Aim 
1. To find out the prevalence of metabolic syndrome in urban low 
socioeconomic group patients with symptomatic coronary artery disease 
using modified International Diabetic Federation (IDF) consensus worldwide 
definition of the metabolic syndrome, 2005. 
2. To analyze the differences in the prevalence of metabolic syndrome among 
age groups, sex, social class and chronic and acute coronary syndromes. 
Objectives 
1. To diagnose symptomatic coronary artery disease in low socioeconomic 
group patients. 
2. To classify patients in to social classes based on family income. 
3. To measure waist circumference, blood pressure, fasting blood sugar, 
fasting high density lipoprotein (HDL) cholesterol and triglyceride. 
4. To find out the prevalence of Central Obesity, Hypertension, Impaired 
Fasting Glucose or Diabetes mellitus, Hypertriglyceridemia and low HDL 
cholesterol and to analyze the differences in their prevalence among the 
age groups, sex, social class and chronic and acute coronary syndromes. 
5. To apply modified IDF, 2005 definition for metabolic syndrome to the data 
and diagnose metabolic syndrome. 
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6. To find the prevalence of metabolic syndrome and analyze the differences 
in its prevalence among the age groups, sex, social class and chronic and 
acute coronary syndromes. 
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Review of Literature 
Some 250 years ago, JB Morgagni with the help of only a knife for anatomical 
dissection, an acute mind, and an observational skillfulness was able to identify the 
intraabdominal and mediastinal fat accumulation in android obesity.7  He clearly 
described the association between visceral obesity, hypertension, hyperuricemia, 
atherosclerosis and obstructive sleep apnea syndrome, long before the modern 
recognition of this syndrome. The concept of insulin resistance is more than 250 
years old and was first described in the 20th century by Himsworth, when in Lancet 
he wrote about subdivision of diabetes into insulin sensitive and insulin resistance in 
1936. Yet it needed Prof. Gerald Raeven who delivered the famous Banting Oration8 
in 1988 to introduce the concept of Insulin Resistance. But he surprisingly missed 
obesity or visceral obesity from the definition which was later added as a crucial 
abnormality. Several terms are used for the same entity namely, Insulin Resistance 
Syndrome, Reaven’s Syndrome, Metabolic Syndrome, Deadly Quartet, CHAOS 
(Coronary artery disease, High Blood Pressure, Adult Onset Diabetes (type 2), 
Obesity, and Stroke), New World Syndrome, Civilization Syndrome, Syndrome ‘X’ 
etc. The latest term used is ‘Metabolic Syndrome’ as per ATP III and WHO.9 The 
clusters which make this syndrome and its etiopathogensis will keep getting varied 
in different ethnic populations, regions and countries. Factors like migration, 
socioeconomic status, lifestyle, nutrition habits play important role. 
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Definitions of Metabolic Syndrome (MS) 
Different definitions have been put forth by IDF, WHO, NCEP-ATP III and 
EGIR. While most definitions agree on essential components, i.e., glucose 
intolerance, obesity, hypertension and dyslipidemia, they differ in the cut-off point 
for criteria of each component of the cluster and the way of combining them to 
define MS. The definition used in WHO report, centers on diabetes and insulin 
resistance, whereas, the ATP III guidelines gives equal weightage to abdominal 
obesity, hypertension, hyperglycemia, hypertriglyceridemia and low HDL 
cholesterol. The IDF is closest to ATP III in that it includes the same variable but it 
differs in that central obesity is an essential component. Also waist measurement is 
set at a lower level than in ATP III and is ethnic-specific and the fasting 
hyperglycemia is set at the new American Diabetic Association (ADA) cut point for 
impaired fasting glucose (IFG). Moreover, it does not include of insulin resistance 
and hyperglycemia is not an obligatory component, which sets it apart from WHO 
and EGIR definitions.   
The IDF, 2005, ATP III and WHO definitions are given in table 1. The 
European Group for the study of Insulin Resistance (EGIR) definition for metabolic 
syndrome is as follows: 
1. Central obesity defined as waist ≥94cm (men), ≥80cm (women). 
2. Blood pressure ≥140/≥90mmHg, or treated for hypertension. 
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3. Triglycerides >2.0 mmol/L, or HDL – cholesterol <1.0 mmol/L, or 
treated for dyslipidemia. 
4. Fasting plasma glucose >6.1 mmol/L, but non-diabetic. 
5. Presence of fasting hyperinsulinemia (i.e., levels falling in the highest 
25% of the non-diabetic population). 
Diagnosis of MS is made by presence of fasting hyperinsulinemia and two of the 
other factors mentioned above. 
Table 1 
 
Risk factors  IDF consensus (2005)11 ATPIII criteria (2001)12 WHO criteria (1999)13 
Obesity/abdominal 
obesity 
 
Waist circumference ≥90 
cm 
(m)*, ≥80 cm (f)** – South 
Asians 
Waist circumference 
≥102 cm (m)*, ≥88 cm 
(f)** 
 
Body mass 
index(BMI) ≥30 
kg/m2 and/or waist-
to-hip ratio >0.90 
(m)*, >0.85 (f)** 
Blood pressure 
 
≥130/≥85 mmHg 
 
≥130/≥85 mmHg 
 
≥140/≥90 mmHg or 
on Medication 
Fasting glucose 
 
≥5.6 mmol/L or pre-
existing diabetes 
≥6.1 mmol/L or on 
medication for diabetes 
Diabetes, impaired 
glucose tolerance or 
insulin resistance 
Triglycerides 
 
≥1.7 mmol/L 
 
≥1.7 mmol/L 
 
Triglycerides ≥1.7 
mmol/L and/or HDL-
C <0.91 mmol/L (m)*, 
<1.01 mmol/L (f)** 
HDL cholesterol 
 
<1.04 mmol/L (m)*, 
<1.3 mmol/L (f)** 
<1.04 mmol/L (m)*, 
<1.3 mmol/L (f)** 
--- 
Microalbuminuria 
 
Not used for diagnosis 
 
Not used for diagnosis 
 
Urinary albumin 
excretion rate 
≥20 μg/min 
Metabolic 
syndrome – 
definition 
 
Abdominal obesity plus 
two or more risk factors 
At least three risk 
factors 
Diabetes, impaired 
glucose tolerance or 
insulin resistance 
plus any two or more 
risk factors 
 
m*– males, f**- females 
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Genetics of MS 
Peroxisome proliferator-activated receptor γ 2 (PPAR γ 2) gene, Peroxisome 
proliferator-activated receptor γ co-activator-1 α (PPARGC1A), leptin, leptin 
receptor, resistin, uncoupling protein-1 (UCP-1), and UCP-2 genes have been 
implicated in common forms of obesity. A recent study conducted in Chennai 
looked at the Thr394Thr, Gly482Ser and +A2962G polymorphisms of the PPARGC1A 
gene showed that the A allele of the Thr394Thr(G→A) polymorphism was associated 
with increased total, visceral and subcutaneous body fat as measured by 
computerized tomography (CT) and dual energy X-ray absorptiometry.14 
 
Adipose Tissue in Metabolic Syndrome 
 
 
Figure 115 - Tissues involved in the metabolic syndrome 
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With weight gain (right-hand side of the figure), the number of macrophages 
in adipose tissue increases, as do the endocrine, paracrine, and autocrine secretory 
patterns for various tissues. Adipocytes and macrophages resident in adipose tissue 
increase secretion of adipokines and cytokines, including IL-6, TNF and leptin.15 
Obesity is associated with all of the risk factors of the metabolic syndrome.16 They 
are mediated by products released by adipose tissue.17 
The humoral changes that are brought about by adipose tissue in obesity include- 
¾ ↑ Non-esterified fatty acid (NEFA) 
¾ ↑ Inflammatory cytokines (TNF-α, IL-6). 
¾ ↑ PAI-I 
¾ ↓ Adiponectin 
¾ ↑ Leptin 
Adeponectin reduces insulin resistance in target tissues. Leptin is an appetite 
suppressant. 
The results of the changes are- 
 TNF-α and IL-6 enhance inflammatory reactions in liver, muscle and 
arterial wall Æ ↑ CRP 
 Increased TNF levels directly interfere with insulin signal transduction 
through effects on the insulin receptor and insulin receptor substrate 1, 
which contributes to insulin resistance.  
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 The most important factor responsible for lipoprotein overproduction 
and dyslipidemia that follows is an increased influx of NEFA into the 
liver. 
 Obesity induces leptin resistance. 
 ↓ Adeponectin induces severe insulin resistance in target tissues. 
 The net result is a chronic inflammatory state associated with insulin 
resistance, dyslipidemia, altered hypothalamic–pituitary–adrenal 
sensitivity, and elevated cytokines. 
Interleukin-6: Studies have demonstrated that about 35% of the production of 
interleukin-6 (IL-6) is from adipose tissue.18 IL-6 decreases glucose uptake by insulin 
sensitive tissues, increases hepatic glucose production, production of NEFA and 
triglycerides.19, 20 IL-6 has been shown to be increased in subjects with diabetes, 
coronary artery disease and in those who take a high fat meal.21-26 
Central (abdominal) Obesity 65% of the body fat is subcutaneous, nearly 20% is 
abdominal and the rest is intramuscular, hepatic fat etc. Abdominal fat plays major 
role in metabolic abnormality.27 Abdominal fat includes intra-abdominal fat 
(visceral) which constitutes approximately 80% and the rest as subcutaneous fat. 
Obesity is considered to be the link between insulin resistance and metabolic 
abnormalities which includes diabetes, hypertension and dyslipidemia, all of which 
are risk factors for coronary artery disease. 28 The visceral fat stored beneath the 
muscles and wrapped around the internal organs is considered to be the most 
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‘atherogenic’, ‘diabetogenic’, and ‘hypertensinogenic’ fat depot of the human     
body. 29-31 
 
Figure 2 36 Development of atherogenic dyslipidemia 
Atherogenic Dyslipidaemia describes the combination of raised triglycerides (TG) 
and low concentrations of HDL-c together with elevated apolipoprotein B (Apo B), 
small dense LDL and small HDL particles, all of which are independently 
atherogenic32, and which is commonly observed in patients with both type 2 diabetes 
and the metabolic syndrome. Low HDL-c and high TG levels are frequently found 
with insulin resistance, with or without type 2 diabetes33, and both are risk factors 
for coronary heart disease (CHD). 34, 35 
Prothrombotic State Prothrombotic defects in MS involve increased levels of 
Plasminogen Activator Inhibitor- I (PAI-I), fibrinogen, factor VII and platelet 
abnormalities.37 Some of the prothrombotic factors may be involved in the 
atherogenic process itself.38  These and other likely enhance the thrombotic response 
to acute plaque ruptures or plaque erosions.39 
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Proinflammatory State Atherogenesis is an inflammatory process. This 
inflammatory process has two major components: 
¾ Tissue injury – lipid abnormalities, hypertension, hyperglycemia and 
thrombotic factors inflict direct injury on the arterial wall. 
¾ Response to injury – infiltration and cellular uptake of lipids, release of 
bioactive molecules by macrophages, and proliferation and collagen 
deposition by smooth muscle cells.40 
These responses apparently elicit secondary inflammatory responses that include 
increased synthesis of acute phase reactant by the liver.  Among the latter are C-
reactive protein and fibrinogen, this may travel to site of arterial injury and enhance 
the inflammatory response.41 Evidence is growing that an elevation of serum CRP 
levels predicts the occurrence of the major CVD events and development of type 2 
diabetes. 42, 43 Persons with metabolic syndrome commonly have high levels of    
CRP. 44 
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“The Asian Indian Phenotype” 
 “South Asians can be classified as metabolically obese”.45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
   Table 2 
 
Associations of insulin resistance and other cardiovascular risk factors in South Asians 
Factors with evidence of positive association Factors with weak or no evidence of 
association 
Excess body fat 
Abdominal obesity 
High truncal subcutaneous fat 
Low birth weight 
High levels of procoagulant factors 
C-reactive protein 
Intramyocellular triglycerides 
Leptin 
 
Neel's “Thrifty Gene” Hypothesis46: Increased ability of Asian Indians to store fat 
may have come as a survival advantage when subjected to famine during evolution. 
Asian Indian 
Phenotype
↑ Inflammatory 
markers; CRP 
↑  Insulin levels/insulin 
resistance 
↓ Level of 
Adeponectin
Greater ethnic/genetic susceptibility to 
Type 2 DM 
↑ Prevalence of Type 2 
DM and CAD 
↑ Abdominal 
Obesity 
Lower threshold 
for BMI 
Characteristic Dyslipidemia: 
↑HDL, ↓TG, ↑Small dense 
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This selective pressure would have enriched the genes that facilitate fat storage, 
predisposing them to obesity and hence glucose intolerance. 
Barker’s “Thrifty Phenotype” Hypothesis47, 48: In bad conditions, a pregnant female 
can modify the development of her unborn child such that it will be prepared for 
survival in an environment in which resources are likely to be short, resulting in a 
thrifty phenotype. Individuals with a thrifty phenotype will have a smaller body 
size and a lowered metabolic rate. Low birth weight (LBW) predisposes to adult 
onset metabolic diseases. 
The Asian Indian Phenotype is characterized by-- 
 Higher body fat per unit BMI.49 
 Higher body fat for given waist circumference.51-53 
 Lower prevalence of obesity as defined by body mass index.50 
 Larger waist circumference and waist: hip ratio for given BMI.50 
 Larger high waist-hip ratio for given waist circumference.49  
 Greater degree of central obesity.50 
 Increased insulin resistance for any given body fat.51-53 
 Less lean body mass (particularly in lower limbs); Sarcopenia.49,54, 55 
Mohan et al., have recently shown that CRP levels do not appear to mediate 
the relationship between the body fat and CHD.56 Absence of any relationship 
between intramyocellular lipids (IMCL) and insulin sensitivity has been reported in 
South Asians in UK and Asian Indians in India57, 58, but it is related to excess body fat 
and abdominal obesity.57 High body fat, often at BMI values that are in non-obese 
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range is another characteristic phenotypic feature of Asian Indians, reported by 
several groups, including Banerji et al in Asian Indians in USA (mean BMI, 24.5 
kg/m2, body fat ~33%) and Dudeja, Misra et al in Asian Indians in India (mean BMI 
23.3 kg/m2, body fat ~35%).49  
In the light of these new researches, anthropometric values for Asian Indians 
are modified. According to provisional recommendations of WHO, BMI should be 
maintained between 19-23 kg/m2.59 Waist circumference should be maintained <90cm 
for men and <80cm for women. 
MS as CVD Risk Factor 
 Individuals with MS have two times higher risk for mortality due to 
myocardial infarction or stroke and three times as likely to develop, myocardial 
infarction or stroke compared to people without MS. 60  The relation of insulin 
resistance to cardiovascular risk, particularly CAD has been well established in 
many prospective studies in the West. In 1209 Finnish men aged 42-60years, the 10-
year CVD risk was increased 2.1- and 2.5- fold with the ATP III and WHO MS 
definitions, respectively. 61 The same study found that the risk of death from CVD 
was increased by 2.63-2.96 times and the risk of death from any cause was increased 
1.87-2.11 times with the presence of the MS. The MS alone predicted ~25% of all new-
onset CVD. 61 The DECODE study reported that the presence of MS increased all-
cause and CVD mortality by 1.2-2.8 times. 62 In the WOSCOPS (West of Scotland 
Coronary Prevention Study), MS defined by ATP III definition was associated with 
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1.8-fold increase in CHD risk, but after adjusting for other risk factors, a more 
modest 1.3-fold increase was observed. 63 
Recommendations for treatment [IDF] 
Patients should undergo a full cardiovascular risk assessment (including 
smoking status) in conjunction with the following: 
Primary Intervention: Healthy lifestyle promotion. This includes: 
• moderate calorie restriction (to achieve a 5–10 per cent loss of body 
weight in the first year) 
• moderate increase in physical activity 
• change in dietary composition 
The results of Finnish and American prevention of diabetes studies have shown the 
marked clinical benefits associated with a small weight loss in terms of preventing 
(or at least delaying by several years) the conversion to type 2 diabetes among high-
risk individuals with glucose intolerance who were, generally, obese.64, 65 
Secondary Intervention: 
Drug therapy may be required to treat the metabolic syndrome in those who are 
considered to be at high risk for CVD. Specific pharmacological agents are not yet 
available that can modulate the underlying mechanisms of the metabolic syndrome 
as a whole. Current practice is to treat the individual components of the syndrome.  
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Treatment of the Individual Components of the Metabolic Syndrome 
Atherogenic Dyslipidaemia 
Primary aims for therapy: 
¾ Lower TG (as well as lowering ApoB and non-HDL cholesterol) 
¾ Raise HDL-c  levels. 
¾ Reduce LDL-c  levels (elevated levels represent a high risk in the metabolic 
syndrome) 
Options: 
¾ Fibrates (PPAR alpha agonists) improve all components of atherogenic 
dyslipidaemia and appear to reduce the risk for CVD in people with 
metabolic syndrome. The Veterans Affairs High-Density Lipoprotein 
Intervention Trial (VA-HIT) showed that raising HDL-c concentrations using 
a fibrate in patients with well-established CHD and both a low HDL-c and a 
low LDL-c level will significantly reduce the incidence of major coronary 
events.33 
¾ Statins to reduce all ApoB-containing lipoproteins and to achieve ATP III 
goals for LDL-c as well as for non-HDL-c (ATP III, 2001). Several clinical 
studies have confirmed the benefits of statin therapy.66-68 
¾ Fibrates in combination with statins but may be complicated by side effects 
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Elevated Blood Pressure 
Primary aims for therapy: 
¾ Categorical hypertension (BP ≥140/≥ 90 mm Hg) should be treated according 
to the USA Seventh Report of the Joint National Committee on prevention, 
detection, evaluation and treatment of high blood pressure (JNC 7) 
recommendations.69 
¾ In patients with established diabetes, antihypertensive therapy should be 
introduced at BP ≥130/≥80 mm Hg. 
Options: 
¾ Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor 
Blockers are useful antihypertensive drugs, with some clinical trials (but not 
all) suggesting they carry advantages over other drugs in patients with 
diabetes. At this time, however, the majority of clinical trials suggest that the 
risk reduction associated with antihypertensive drugs is the result of blood 
pressure lowering per se and not due to a particular type of drug. 
¾ No particular agents have been identified as being preferable for 
hypertensive patients who also have the metabolic syndrome. 
Insulin resistance and hyperglycemia 
There is growing interest in the possibility that drugs that reduce insulin resistance 
will delay the onset of type 2 diabetes and will reduce CVD risk when metabolic 
syndrome is present. The Diabetes Prevention Program (DPP) showed that 
metformin therapy in patients with prediabetes will prevent or delay the 
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development of diabetes and recent thiazolidinedione studies have also 
demonstrated efficacy in delaying or preventing type 2 diabetes in patients with 
impaired glucose tolerance (IGT) and insulin resistance.70-72 Similarly, other studies 
have shown that both acarbose and orlistat can be used to delay the development of 
type 2 diabetes in patients with IGT.73, 74 Data do not yet exist to show whether any of 
the currently available thiazolidinediones reduce the risk of CVD in those with the 
metabolic syndrome, IGT or diabetes. 
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Recognition of Coronary Artery Disease 
Classification: 
1. Chronic stable Angina 
2. Acute coronary syndrome 
• Unstable angina 
• Non-ST elevation MI 
• ST elevation MI 
The first step is to a detailed description of the symptom complex in order to 
characterize the chest pain or discomfort. Five descriptors typically are considered.75 
1. Location, 
2. Quality, 
3. Duration of the discomfort, 
4. Inciting factors, and  
5. Factors relieving pain. 
Clinical classification of angina76 
Typical angina (definite) 
1. Substernal chest discomfort with a characteristic quality and duration that is 
2. Provoked by exertion or emotional stress and 
3. Relieved by rest or nitroglycerin. 
Atypical angina (probable) 
     Meets two of the above characteristics. 
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Noncardiac chest pain 
     Meets one or none of the typical anginal characteristics. 
Stable Angina: Stable angina is characterized by a deep, poorly localized chest or 
arm discomfort (rarely described as pain) that is reproducibly associated with 
physical exertion or emotional stress and relieved within 5 – 15 minutes by rest or 
sublingual nitroglycerine, or both. The characteristics of the stable angina usually 
unchanged for 60 days.  
Anginal Equivalent: Symptoms of myocardial ischemia other than angina such as 
dyspnea, fatigue, faintness and eructations, are particularly common in the elderly.77 
Acute Coronary Syndrome: 
Unstable Angina: Angina pectoris (or equivalent type of ischemic discomfort) with 
at least one of the following three features78:  
1. Occurring at rest (or with minimal exertion) and usually lasting more 
than 20 minutes (if not interrupted by nitroglycerin), 
2. Being severe and described as frank pain and of new onset (i.e., within 1 
month), 
3. Occurring with a crescendo pattern (i.e., more severe, prolonged or 
frequent than previously). 
Crescendo Angina79: worsening of angina can be defined as symptoms that result in 
at least 1 Canadian Cardiovascular Society (CCS) class increase or to at least CCS 
Class 3 severity. 
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Secondary Unstable Angina: This form of unstable angina is precipitated by an 
imbalance in myocardial oxygen supply and demand caused by condition extrinsic 
to the coronary arteries in patients with prior coronary stenosis and chronic stable 
angina. 79, 81   
Canadian Cardiovascular Society (CCS) Grading of Angina Pectoris 
Table 3.80 
 
Grade 
 
Description 
Grade I “Ordinary physical activity does not cause angina.”  
• Walking and climbing stairs.  
• Angina with strenuous, rapid or prolonged exertion at work or 
recreation. 
Grade II “Slight limitation of ordinary activity”.  
• Walking or climbing stairs rapidly.  
• Walking uphill. 
• Walking or stair climbing after meals. 
• In cold, or in wind, or under emotional stress.  
• During the few hours after awakening.  
• Walking > 2 blocks on the level.  
• Climbing >1 flight of ordinary stairs at a normal pace and in 
normal conditions. 
Grade III “Marked limitation of ordinary physical activity”.  
• Walking 1 or 2 blocks on the level and  
• Climbing 1 flight of stairs in normal conditions and at normal 
pace. 
Grade IV “Inability to carry on any physical activity without discomfort -- anginal 
syndrome may be present at rest.” 
 
Non-ST elevation MI (NSTEMI): NSTEMI represents a clinical condition presenting 
very similarly to unstable angina but with the evidence of myonecrosis by some 
form of cardiac markers without ST segment elevation on ECG. 
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ST elevation MI: The classic World Health Organization criteria for an acute MI 
require that two of the following three elements82 be present: 
1. A history suggestive of coronary ischemia for a prolonged period (>30 min), 
2. Evolutionary changes in serial ECGs suggestive of MI, 
3. A rise and fall in serum cardiac markers consistent with myonecrosis. 
The pain of myocardial infarction is typically substernal, diffuse, with a squeezing or 
pressure quality. It may radiate to the neck or jaw, shoulders, or arms. Most often, 
the pain is accompanied by additional symptoms, such as lightheadedness, nausea 
or vomiting, diaphoresis, or shortness of breath. The symptoms of myocardial 
infarction last longer than 30 minutes, and do not respond completely to 
nitroglycerin. Elderly or diabetic patients are prone to atypical symptoms, such as 
nausea or dyspnea as the sole symptoms of infarction. As many as one-fourth of 
myocardial infarctions are “silent” — that is, whatever symptoms were present did 
not impress the patient enough to seek medical care, or even to remember the 
incident. 
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Secondary Precipitant of Myocardial Ischemia 
Table 4 
 
Increased Myocardial Oxygen Demand 
 
Decreased Oxygen Supply 
 
• Fever  
• Thyrotoxicosis 
• Tachycardia 
• Malignant Hypertension 
• Pheochromocytoma  
• Hypertension 
• Aortic Stenosis 
• High Output State 
• Pregnancy 
• Drugs: Cocaine, Amphetamine 
 
• Anemia  
• Hypotension 
• Hypoxemia (pneumonia, CCF 
etc.) 
• Carbon Monoxide Poisoning 
• Polycythemia Vera 
• Hyperviscosity Syndromes 
 
 
Braunwald Clinical Classification of Unstable Angina or Non-ST Elevation 
Myocardial Infarction. 
Table 5.81 
Clinical Circumstances 
 
Severity A—Develops in 
Presence of Extra 
cardiac Condition 
That Intensifies 
Myocardial Ischemia 
(Secondary UA) 
B—Develops in 
Absence of Extra 
cardiac Condition 
(Primary UA) 
C—Develops Within 
2 wk of AMI (Post 
infarction UA) 
I—New onset of 
severe angina or 
accelerated angina; 
no rest pain 
IA IB IC 
II—Angina at rest 
within past month 
but not within 
preceding 48 h 
(angina at rest, sub 
acute) 
IIA IIB IIC 
III—Angina at rest 
within 48 h (angina 
at rest, acute) 
IIIA IIIB-Tnegetive 
  
IIIB-Tpositive  
IIIC 
 
UA indicates unstable angina; AMI, acute myocardial infarction. 
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Socioeconomic Status and Poverty 
Poverty is the most obvious problem in India. According 1987-88 estimates 
about 29.9% population of the country is living below “poverty line” of which 82.5% 
are living in the rural areas and 17.5% in urban areas. The “poverty line” is defined 
as the expenditure required for a daily calorie intake of 2400 per person in rural 
areas and 2100 in urban areas. This expenditure is officially estimated at Rs. 181.50 
per capita per month in rural areas and Rs. 209.50 in urban areas at 1991-92 prices. It 
varies from place to place. The poverty line in different states, cities, villages is 
drawn at a different level.83  When these values are adjusted to prevalent inflation of 
2006-07, the values are Rs. 4438 per capita per month in rural areas and Rs. 5123 per 
capita per month in urban areas, respectively. 
All over the world the social scientists have considered occupation as the 
most important determinant of the level of social standing of an individual in 
society. In India, Prasad's classification of 1961, further modified in 1968 84 and 1970 85 
is based on per capita income is used. The income limits emphasize only the need for 
updating this classification with time. Realizing this need, P.Kumar 86 linked Prasad's 
classification (1961) with the All India Consumer Price Index (AICPI) as both of them 
shared the same base year of 1961. 
To get modified social class adjusted to prevalent inflation, value in Prasad’s 
Classification should be multiplied by a factor R.  
R = Value of CPI (4.93) / 100.   
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CPI=Consumer Price Index  
4.93 = A multiplication factor, which transforms current values of CPI into a 
hypothetical value of CPI in relation to the base year of 1961.   
The All-India CPI (UNME) for January, 2007 is 496. 87    
Hence, R =24.4528.  
Table 6 
 
Monthly Income Limits (Rs) Social 
Class Prasad’s Classification 
(1961) 
Modified classification for the 
month of January 2007 
I 100 & above 2445 - 5100 
II 50 - 99 1225 - 2444 
III 30 - 49 735 - 1224 
IV 15 - 29 370 - 734 
V Below 15 Below 369 
 
Prevalence 
The term “disease prevalence” refers to the total numbers of all individual 
who have an attribute or disease at a particular time (or during a particular period) 
divided by total the population at risk of having the attribute at this point of time or 
midway through the period. 88 
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Materials and Methods 
Study Design: 
A cross sectional study, with analysis of the metabolic parameters for differences. 
Ethical Clearance: Obtained 
Informed consent: Obtained 
Criteria for MS: 
Modified International Diabetic Federation consensus worldwide definition of the 
Metabolic Syndrome, 2005. 
Study Period: 
September, 2006 to August, 2007 (12 months). 
Study Population: 
All patients belonging to low socioeconomic group (family income <Rs.5100 per 
month), attending medical outpatient department or those who are getting admitted 
in medical ward of Govt. Kilpauk Medical College (KMC), Chennai with coronary 
artery disease (CAD). 
Sample Size: 
113 patients, i.e. 38 female patients and 75 male patients. 
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Inclusion Criteria: 
Patients’  
1. Those who attend medical outpatient department or getting admitted in 
medical ward at KMC. 
2. With family income less than Rs.5100 per month. 
3. Who live in Chennai city. 
4. With age more than 20 years. 
5. With symptoms suggestive of CAD.  
6. With ECG features suggestive of CAD or significant CK-MB elevation. 
Exclusion Criteria: 
Patients’ 
1. Children, adolescents and those with age less than 20 years. 
2. With nonanginal chest pain. 
3. With asymptomatic CAD. 
4. With ECG changes which are not due to myocardial ischemia or infarction. 
Data Collection: 
1. Socio-demographic profile. 
 Name, age, sex, address and family income recorded in the 
questionnaire. 
 Patients with family income less than Rs. 5100 per month are 
included and classified into 5 Modified Prasad’s socio-economic 
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classes, which is adjusted for the existing inflation by multiplying 
with current All India Consumer Pricing Index (AICPI) (2006 – 07). 
2. Recognition of CAD. 
• Patients enquired for typical history of angina and its duration,  
previous history of CAD and treatment received for the same. 
• Vital parameters recorded. 
• Cardiac, Respiratory, Abdomen and Neurologic Systems 
examined for signs of complications of CAD. 
• 2 ECGs (12 lead) taken 24 hours apart, looking for changes 
suggestive of myocardial ischemia and infarction (new or old). 
• Simultaneously 2 venous blood samples are drawn, 24 hours 
apart and Creatine Kinase – MB (units per liter) levels assessed 
by commercially available CK – MB kit from Ranbaxy 
diagnostics. 
• With information available patients classified into 2 groups, 
namely, Chronic CAD and Acute Coronary Syndrome (ACS). 
3. Screening for parameters of MS. 
Waist Circumference: It is measured at a level midway between the 
lower rib margin and iliac crest with the tape all around the body in 
horizontal position, at the end of normal gentle exhalation, in morning 
before breakfast after emptying bowel and bladder. Patients are asked 
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to remove their clothes, except for light underwear. If this is not 
possible cultural reasons, measurement taken without heavy outer 
garments. Tight clothing, including the belt, should be loosened and 
the pockets emptied, standing with their feet fairly close together 
(about 12-15 cm) with their weight equally distributed to each leg. The 
tape should be loose enough to allow the observer to place one finger 
between the tape and the subject's body. Measurements are recorded to 
the resolution of 0.1cm. 
Blood Pressure: Blood pressure is measured in right arm supine 
position using mercury manometer using appropriate size cuff, 
recorded in mmHg to the precision of 0.2mmHg. 2 reading are 
recorded. Higher reading among systolic and diastolic blood pressure 
is taken for analysis. Patient is asked for previously diagnosed 
hypertension and response recorded. 
Fasting Plasma Glucose measured (in mg/dL) by semi quantitative O’ 
Toluidine method from venous blood sample drawn in morning 
following at least 8 hours of fasting. Patient is asked for previously 
diagnosed hypertension and response recorded. 
Triglyceride measured (in mg/dL) by enzymatic colorimetric method 
and HDL measured (in mg/dL) by selective immune precipitation 
photometric method from venous blood sample drawn in morning 
following at least 8 hours of fasting at Thyrocare Technologies Limited, 
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Mumbai. Patient is asked for previously diagnosed lipid abnormality 
for which treatment is being taken and response recorded. 
4. Statistical analysis. 
• Statistical analysis is done using Windows based NCSS 97 
software.  
• Measures of central tendency, dispersion and distribution of the 
variables obtained.  
• Prevalence of Central Obesity, Hypertension, Diabetes or 
Impaired Fasting Glucose (IFG), Hypertriglyceridemia, Low 
HDL and Metabolic Syndrome calculated in the study sample, 
among sexes, social classes and in chronic and acute coronary 
syndrome. 
• X2 test used as the test as significance to find difference between 
the proportions of discrete variables. P<0.05 taken as significant. 
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The IDF consensus worldwide definition of the metabolic syndrome 
modified for Indians 
 
 Central Obesity (defined as waist circumference ≥ 90cm for Indian men and ≥ 80cm 
for Indian women)  
Plus any two of the following four factors: 
1. Raised TG level:  >150 mg/dL (1.7 mmol /L), or specific treatment for this 
lipid abnormality 
2. Reduced HDL Cholesterol: < 40 mg/dL (1.03 mmol/L) in males and < 50 
mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid 
abnormality 
3. Raised Blood Pressure: systolic BP ≥130 or diastolic BP ≥85 mm Hg, or 
treatment of previously diagnosed hypertension 
4. Raised Fasting Plasma Glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or 
previously diagnosed type 2 diabetes 
If above 5.6 mmol/L or 100 mg/dL, OGTT is strongly recommended but is not 
necessary to define presence of the syndrome. 
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Results  
Baseline Characteristics: Total 113 patients with coronary artery disease whose 
income less than Rs. 5100 per month participated in the study. 38 (33.6%) were 
females. 75 (66.4%) were males. Age groups were near normally distributed with the 
sample mean being 54.27years (CI: 54.3±23years). Maximum numbers of patients 
(70) are in the age groups 40 – 60 years. Youngest patient is 25years and oldest being 
80years old. 
Mean of age for males (CI: 55.49± 22years) and females (CI: 51.87±24.7years) 
lie within one standard deviation from sample mean. Males represent older age (>60 
years) group more than females. Age distribution in males is negatively skewed.  
Social class distribution is positively skewed, i.e., income being negatively 
skewed. Class I & II (i.e., Rs.1200 – 5100) represent > 70% of sample both in males 
and females. There has been no representation of lower income groups, i.e., social 
class IV and V, from < 40 years and >60 years. Since there is inadequate 
representation of the social classes, especially, class IV and V, social classes were 
excluded from further analysis. 
49 (43.4%) patients had chronic CAD and 64 (56.6%) patients had ACS. 
Among males 37 had chronic CAD and 38 had ACS. Among females 12 had chronic 
CAD and 26 had ACS. Social groups IV and V had lesser representation in both 
chronic CAD and ACS. 
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Distribution of Age Groups and Sex in the Sample 
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     Figure 4             Figure 5 
 
 
 
 
 
      Table 7 
Sex 
Females Males 
Total Age 
Count % Count % Count % 
20 To 39 6 5.3 8 7.1 14 12.4 
40 To 59 25 22.1 45 39.8 70 61.9 
Over 60 7 6.2 22 19.5 29 25.7 
Total 38 33.6 75 66.4 113 100.0 
  
 
 
 
 
 
 
35 
 
 
 
Distribution of Social Class 
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   Figure 6       Figure 7 
 
 
 
             Table 8 
Social Class  
I II III IV V 
Total 
Females 9 17 9 3 0 38 
Males 24 33 12 3 3 75 
Total 33 50 21 6 3 113 
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Age Groups and Sex in Social Classes 
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Table 9 
 
 
 
 
 
 
 
 
Females 
Table 10 
Age Social Class Total 
 I II III IV V  
20 To 39 0 4 2 0 0 6 
40 To 59 9 9 4 3 0 25 
Over 60 0 4 3 0 0 7 
Total 9 17 9 3 0 38 
 
 
 
 
Males 
Table 11 
Age Social Class Total 
 I II III IV V  
20 To 39 3 3 2 0 0 8 
40 To 59 18 21 3 3 0 45 
Over 60 3 9 7 0 3 22 
Total 24 33 12 3 3 75 
 
 
 
 
 
 
Social Class Age 
I II III IV V 
Total 
20 To 39 3 7 4 0 0 14 
40 To 59 27 30 7 6 0 70 
Over 60 3 13 10 0 3 29 
Total 33 50 21 6 3 113 
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Distribution of Coronary Artery Disease 
 
 
 
 
Figure 10 
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  Table 12 
Sex Chronic CAD ACS Total 
 count % count % count % 
Females 12 10.6 26 23.0 38 33.6 
Males 37 32.7 38 33.6 75 66.4 
Total 49 43.4 64 56.6 113 100.0 
  
 
 
Table 13 
Age Chronic CAD ACS Total 
 count % count count count % 
20 To 39 2 1.8 12 10.6 14 12.4 
40 To 59 30 26.5 40 35.4 70 61.9 
Over 60 17 15.0 12 10.6 29 25.7 
Total 49 43.4 64 56.6 113 100.0 
 
 
 
Table 14 
Social Class  
I II III IV V 
Chronic CAD 12 22 12 0 3 
ACS 21 28 9 6 0 
Total 33 50 21 6 3 
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Central Obesity 
Mean of waist circumference of the sample is 87.13 (95% CI: 87±21) cm and 
that of females and males being 84.31 (95% CI: 84±15.7) cm and 88.56 (95% CI: 
88.6±22.6) cm, respectively.  
59 patients (52.2%) had central obesity. 64.2% patients in age group <40years, 
41.4% in age group 40-60years and 72.4% in age group >60years had central obesity. 
This increase in prevalence of central obesity among younger (<40year) and older 
age group (>60years) is significant (X2- 08.82, p=0.01). 
23(60.5%) female patients 36 (48%) male patients had central obesity, 
respectively. There is no significant difference in the prevalence of central obesity 
between females and males (X2-1.59, p=0.21). 
19 (38.78%) patients with chronic CAD and 40 (62.5%) patients with ACS had 
central obesity. The increase in the prevalence of central obesity in ACS is significant 
(X2-6.26, p=0.01). 
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Central Obesity in Age Groups 
 
 
Figure 14 
 
     Table 15 
Central Obesity Age Groups 
Absent Present 
Total 
 
20 To 39 5 9 14 
40 To 59 41 29 70 
Over 60 8 21 29 
Total 54 59 113 
 
 
Central Obesity in Males and Females 
 
 
Figure 15 
 
           Table 16 
Central Obesity Sex 
Absent Present 
Total 
 
Female 15 23 38 
Male 39 36 75 
Total 54 59 113 
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Hypertension 
Mean of SBP and DBP of the sample are 138.53 (95% CI: 138.5±44) mmHg and 
88.85 (95% CI: 88.85±23.9) mmHg, respectively and that of females 145.26 (95% CI: 
145±30.8) mmHg and 92.89 (95% CI: 92.89±21.8) mmHg, respectively and that of 
males being 135.12 (95% CI: 135±48) mmHg and 86.8 (95% CI: 86.8±24) mmHg, 
respectively.  
84 patients (74.34%) had hypertension. 71.43% patients in age group <40years, 
77.14% in age group 40-60years and 68.96% in age group >60years had hypertension. 
There is no significant difference in prevalence of hypertension among age group 
(X2- 00.79, p=0.67). 
33(86.84%) female patients 51 (68%) male patients had hypertension, 
respectively. This increase in prevalence of hypertension among females as 
compared to males is significant (X2-04.69, p=0.03). 
31 (63.27%) patients with chronic CAD and 53 (82.81%) patients with ACS had 
hypertension. Increase in the prevalence of hypertension in ACS is significant (X2-
05.56, p=0.02). 
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Hypertension in Age Groups 
 
 
Figure 16 
 
       Table 17 
Hypertension Age 
Absent Present 
Total 
20 To 39 4 10 14 
40 To 59 16 54 70 
Over 60 9 20 29 
Total 29 84 113 
 
 
Hypertension in Males and Females 
 
 
Figure 17 
 
        Table 18 
Hypertension Sex 
Absent Present 
Total 
Female 5 33 38 
Male 24 51 75 
Total 29 84 113 
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Diabetes and IFG 
Mean of FBS of the sample is 130.31 (95% CI: 130.31±132) mg/dL and that of 
females and males being 126.72 (95% CI: 92.89±128.7) mg/dL and 137.39 (95% CI: 
137.39±139) mg/dL, respectively.  
57 patients (50.44%) had diabetes or IFG. 50% patients in age group <40years, 
40% in age group 40-60years and 75.86% in age group >60years had diabetes or IFG. 
This increase in prevalence of Diabetes and IFG among younger (<40year) and older 
age group (>60years) is significant (X2- 10.55, p=.005). 
21 (55.26%) female patients 36 (48%) male patients had diabetes or IFG, 
respectively. There is no significant difference in the prevalence of diabetes and IFG 
between females and males (X2-00.53, p=0.47). 
22 (44.9%) patients with chronic CAD and 35 (54.69%) patients with ACS had 
diabetes or IFG. There is no significant difference in the prevalence of diabetes and 
IFG between chronic CAD and ACS (X2-01.06, p=0.30). 
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Diabetes and IFG in Age Groups 
 
 
                                                            Figure 18 
 
      Table 19 
DM and IFG Age 
Absent Present 
Total 
20 To 39 7 7 14 
40 To 59 42 28 70 
Over 60 7 22 29 
 
 
Diabetes and IFG in Males and Females 
 
 
 
                                                                 Figure 19 
 
          Table 20 
DM and IFG Sex 
Absent Present 
Total 
Female 17 21 38 
Male 39 36 75 
Total 56 57 113 
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Hypertriglyceridemia 
Mean of triglyceride level of the sample is 159.71 (95% CI: 159.71±160.6) 
mg/dL and that of females and males being 150.14 (95% CI: 150.14±110.4) mg/dL and 
164.56 (95% CI: 164.56±180.7) mg/dL, respectively.  
48 patients (42.48%) had hypertriglyceridemia. 50% patients in age group 
<40years, 32.86% in age group 40-60years and 62% in age group >60years had 
hypertriglyceridemia. This increase in prevalence of hypertriglyceridemia among 
younger (<40year) and older age group (>60years) is significant (X2- 07.53, p=0.02). 
12 (31.58%) female patients 36 (48%) male patients had hypertriglyceridemia, 
respectively. There is no significant difference in the prevalence of 
hypertriglyceridemia between females and males (X2-02.78, p=0.09). 
22 (44.9%) patients with chronic CAD and 26 (40.63%) patients with ACS had 
hypertriglyceridemia. There is no significant difference in the prevalence of 
hypertriglyceridemia between chronic CAD and ACS (X2-00.21, p=0.65). 
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Hypertriglyceridemia in Age Groups 
 
 
                                                                Figure 20 
 
                Table 21 
Age Hypertri 
glyceridemia 20 To 39 40 To 59 Over 60 
Total 
Absent 7 47 11 65 
Present 7 23 18 48 
Total 14 70 29 113 
 
 
 
Hypertriglyceridemia in Males and Females 
 
 
 
                                                            Figure 21 
 
                            Table 22 
Sex Hypertri 
glyceridemia Female Male 
Total 
Absent 26 39 65 
Present 12 36 48 
Total 38 75 113 
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High Density Lipoprotein 
Mean of HDL level of the sample is 44.32 (95% CI: 44.32±21.7) mg/dL and that 
of females and males being 48.07 (95% CI: 48.07±19.4) mg/dL and 42.4 (95% CI: 
42.4±21.9) mg/dL, respectively.  
54 patients (47.79%) had low HDL. 71.42% patients in age group <40years, 
40% in age group 40-60years and 55.17% in age group >60years had low HDL. There 
is no significant difference in the prevalence of low HDL between age groups (X2- 
05.47, p=0.06). 
21 (55.26%) female patients 33 (44%) male patients had low HDL, respectively. 
There is no significant difference in the prevalence of low HDL between females and 
males (X2-01.28, p=0.26). 
25 (44.9%) patients with chronic CAD and 29 (40.63%) patients with ACS had 
low HDL. There is no significant difference in the prevalence of low HDL between 
chronic CAD and ACS (X2-00.36, p=0.55). 
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Low HDL in Age Groups 
 
 
                                                               Figure 22 
 
                   Table 23 
 Age  
Low HDL 20 To 39 40 To 59 Over 60 Total 
Absent 4 42 13 59 
Present 10 28 16 54 
Total 14 70 29 113 
 
 
 
 
Low HDL Males and Females 
 
 
 
                                                              Figure 23 
                                 Table 24 
Sex Low HDL 
Female Male 
Total 
Absent 17 42 59 
Present 21 33 54 
Total 38 75 113 
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Measures of Central Tendency 
 
Table 25 
 
  total female Male 
Age (years) mean 54.27 51.87 55.49 
 Std dev 11.64 12.33 11.17 
 Std error 1.10 2.00 1.29 
 95% CI 54.3±23 52±24.7 55.5±22 
Waist (cm) mean 87.13 84.31 88.56 
 Std dev 10.44 7.84 11.30 
 Std error 0.98 1.27 1.31 
 95% CI 87±21 84±15.7 88.6±22.6 
SBP(mmHg) mean 138.53 145.26 135.12 
 Std dev 22.00 15.38 24.07 
 Std error 2.07 2.49 2.78 
 95% CI 138.5±44 145±30.8 135±48 
DBP (mmHg) mean 88.85 92.89  86.8 
 Std dev 11.93 10.88 11.99 
 Std error 1.12 1.77 1.38 
 95% CI 88.85±23.9 92.89±21.8 86.8±24 
FBS (mg/dL) mean 130.31 126.72 137.39 
 Std dev 66.07 64.43 69.52 
 Std error 6.22 7.44 11.28 
 95% CI 130.31±132 92.89±128.7 137.39±139 
TG (mg/dL) mean 159.71 150.14 164.56 
 Std dev 80.30 55.18 90.36 
 Std error 7.55 8.95 10.43 
 95% CI 159.71±160.6 150.14±110.4 164.56±180.7 
HDL (mg/dL) mean 44.32 48.07 42.4 
 Std dev 10.84 9.68 10.97 
 Std error 1.02 1.57 1.27 
 95% CI 44.32±21.7 48.07±19.4 42.4±21.9 
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X2 Tests for Statistical Difference 
 
 
Table 26 
 
 0 Fr X2  P value H0 Difference 
1. Central Obesity in age groups 2 08.82 0.01 Reject Yes 
in sex 1 01.59 0.21 Accept No 
CAD 1 06.26 0.01 Reject Yes 
2.HTN in age groups 2 00.79 0.67 Accept No 
in sex 1 04.69 0.03 Reject Yes 
CAD 1 05.56 0.02 Reject Yes 
3.DM & IFG in Age groups 2 10.55 .005 Reject Yes 
in sex 1 00.53 0.47 Accept No 
CAD 1 01.06 0.30 Accept No 
4.Hypertriglyceridemia in Age 
groups 
2 07.53 0.02 Reject Yes 
 
in sex 1 02.78 0.09 Accept No 
CAD 1 00.21 0.65 Accept No 
5.Low HDL in Age groups 2 05.47 0.06 Accept No 
in sex 1 01.28 0.26 Accept No 
CAD 1 00.36 0.55 Accept No 
6.MS in Age groups 2 10.25 .006 Reject Yes 
in sex 1 0.004 00.94 Accept No 
CAD 1 02.82 00.09 Accept No 
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Metabolic Syndrome 
54 patients (47.78%) had metabolic syndrome. 50% patients in age group 
<40years, 37.14% in age group 40-60years and 72.41% in age group >60years had 
metabolic syndrome. This increase in prevalence of metabolic syndrome among 
younger (<40year) and older age group (>60years) is significant (X2- 10.25, p=.006). 
18 (47.37%) female patients and 36 (48%) male patients had metabolic 
syndrome, respectively. There is no significant difference in the prevalence of 
metabolic syndrome between female and male patients (X2-0.004, p=00.94). 
19 (38.78%) patients with chronic CAD and 35 (54.69%) patients with ACS had 
metabolic syndrome. There is no significant difference in the prevalence of metabolic 
syndrome between chronic CAD and ACS (X2-02.82, p=00.09). 
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Metabolic Syndrome in Age Groups  
 
 
 
Figure 24 
 
 
                          Table 27 
Metabolic Syndrome Age 
Absent Present 
Total 
20 To 39 7 7 14 
40 To 59 44 26 70 
Over 60 8 21 29 
Total 59 54 113 
 
Prevalence of Metabolic Syndrome in the population under study =  
(Number of patients with Metabolic Syndrome ÷ total number of patients involved 
in the study) ×100 = (54 ×100) ÷11 
= 47.79% 
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Metabolic Syndrome in Males and Females  
 
 
 
Figure 25 
 
    Table 28 
Metabolic Syndrome Sex 
Absent Present 
Total 
Female 20 18 38 
Male 39 36 75 
Total 59 54 113 
 
Prevalence of Metabolic Syndrome among female patients under study =  
(Number of female patients with Metabolic Syndrome ÷ total number of female 
patients involved in the study) ×100 
= (18 ×100) ÷ 38 
= 47.37% 
Prevalence of Metabolic Syndrome among male patients under study =  
(Number of male patients with Metabolic Syndrome ÷ total number of male patients 
involved in the study) ×100 
= (36 ×100) ÷ 75 
= 48% 
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Metabolic Syndrome in CAD  
 
 
          
Figure 26 
 
    Table 29 
Metabolic Syndrome  
Absent Present 
Total 
ACS 29 35 64 
Chronic CAD 30 19 49 
Total 59 54 113 
 
Prevalence of Metabolic Syndrome among patients Chronic CAD =  
(Number of Chronic CAD patients with Metabolic Syndrome ÷ total number of 
Chronic CAD patients involved in the study) ×100 
= (19 ×100) ÷ 49 
= 38.78% 
Prevalence of Metabolic Syndrome among patients with ACS =  
(Number of ACS patients with Metabolic Syndrome ÷ total number of  patients ACS 
involved in the study) ×100 
= (35×100) ÷ 64 
= 54.69% 
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The Prevalence of Metabolic Syndrome and Metabolic 
Parameters 
 
 
 
Figure 27 
 
 
     Table 30 
Prevalence Total Females Males 
Central Obesity 52.21% 60.53% 48% 
Hypertension 74.34% 86.84% 68% 
DM and IFG 50.44% 55.26% 48% 
Hypertriglyceridemia 42.48% 31.58% 48% 
Low HDL 47.79% 55.26% 44% 
Metabolic Syndrome 47.79% 47.37% 47.79% 
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The “U” shaped Distribution in Age Groups  
 
 
X2 Significant 
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Table 31 
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Discussion 
Mean age of the sample being 54.27years (CI: 54.3±23years). The mean age of 
an Asian Indian patient suffering a myocardial infarction is only 50 years.25% of all 
MIs in this population occur under the age of 40 years. 89 
Obesity 
This study shows higher prevalence of obesity (52.2%) in those suffering from 
CAD and living below poverty line.  This is much higher compared to a study 
conducted in the intracountry  migrant population that resides in urban slums, 
where obesity prevalence was 13.9%.49Even in males (48%) and females (60.5%), 
prevalence of obesity is markedly higher compared to the corresponding figures 
from the Nutrition Foundation of India, where the prevalence of obesity is 1% for 
males and 4% for females in the slums while corresponding figures for the middle 
socioeconomic class was 32.2% and 50%, respectively.90 Using EGIR criteria, the 
Chennai Urban Population Study (CUPS), over 35% of the males in the middle-
income group were obese compared to 13% in the low income group. The 
corresponding figures for females were 33% and 24% respectively.91 
  In my study, there was no significant difference in the prevalence of 
central obesity between females and males. Obesity prevalence was 
significantly higher (p=0.01) in ACS (62.5%) as compared to chronic CAD 
(38.78%).Interestingly, there significant increase (p=0.01) in prevalence of 
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central obesity among patients with premature CAD (<40years) and older age 
group (>60 years) forming a “U” shaped distribution. 
Hypertension 
Prevalence of hypertension in my study was 74.34%, whereas overall 
prevalence of hypertension in Chennai Urban Population Study (CUPS) was 21.1%, 
where hypertension was diagnosed using JNC 6 criteria. 92 In another study 
conducted in the intracountry migrant population that resides in urban slums, 
where prevalence of hypertension was 11.7%.49 There is no significant difference 
in prevalence of hypertension among age group. But virtually all studies of 
blood pressure carried out in different populations including India have shown a 
rise of blood pressure with age in both men and women.93  86.84% of female 
patients 68% male patients had hypertension, respectively. This increase in 
prevalence of hypertension among females as compared to males is significant 
(p=0.03). Studies have shown that, greater prevalence of hypertension among urban 
Indian population of women compared to men.94 63.27% patients with chronic 
CAD and 82.81% patients with ACS had hypertension. Increase in the 
prevalence of hypertension in ACS is significant (p=0.02). 
Diabetes and IFG 
50.44% had diabetes or IFG.  This is higher compared to 13.5% 95, 96 in a 
study conducted in Chennai city and 10.3%49 in another study conducted in the 
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intracountry migrant population that resides in urban slums. But in these figures 
IFG is not included. There was significant increase (p=0.005) in prevalence of 
Diabetes and IFG among patients with premature CAD (<40years) and older 
age group (>60 years) forming a “U” shaped distribution. 55.26% of female 
patients 48% of male patients had diabetes or IFG, respectively. A recent cross-
sectional cohort study conducted in Mysore, India found the prevalence of type 2 
diabetes to be 40% in women, versus 34% in men.97 Again this figures do not include 
IFG.  44.9% of the patients with chronic CAD and 54.69% of the patients with 
ACS had diabetes or IFG. There was no significant difference in the 
prevalence of diabetes and IFG among sexes and between chronic CAD and 
ACS. 
Dyslipidemia 
42.48% had hypertriglyceridemia, in contrast to 14.5%49 in the 
intracountry migrant population that resides in urban slums. There was significant 
increase (p=0.02) in prevalence of hypertriglyceridemia among patients with 
premature CAD (<40years) and older age group (>60 years) forming a “U” 
shaped distribution. 31.58% of female patients 48% of male patients had 
hypertriglyceridemia, respectively. 44.9% patients with chronic CAD and 
40.63% patients with ACS had hypertriglyceridemia. There was no significant 
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difference in the prevalence of hypertriglyceridemia among sexes and 
between chronic CAD and ACS. 
47.79% had low HDL as compared to 16.2%49in the intracountry migrant 
population that resides in urban slums.  55.26% female patients 44% male 
patients had low HDL, respectively. 25 (44.9%) patients with chronic CAD 
and 29 (40.63%) patients with ACS had low HDL. There was no significant 
difference in the prevalence of hypertriglyceridemia among age groups, sexes 
and between chronic CAD and ACS. 
Metabolic Syndrome 
Overall prevalence of metabolic syndrome among the study population 
was 47.79% using IDF, 2005 definition. There was significant increase (p=0.006) 
in prevalence of metabolic syndrome among patients with premature CAD 
(<40years) and older age group (>60 years) forming a “U” shaped distribution. 
47.37% of female patients and 48% of male patients had metabolic syndrome, 
respectively. 
Various studies have described prevalence of MS using different 
definitions ranging from 11.2-41.1% as given below. All of them reported 
decreased prevalence of MS in low socioeconomic class people. 
1. Using EGIR criteria, the Chennai Urban Population Study (CUPS -4), 
reported overall prevalence of MS to be 11.2% with the significant 
63 
 
difference between the middle income (18.7%) and low income groups 
(6.5%).91 
2. An earlier study in urban Indian adults aged 20-75years, reported a 
prevalence of MS to be 41.1% using NCEP definition.98 
3. In CURES study, prevalence of MS were 23.2%, 18.3% and 25.8% 
according to the WHO, ATP III and IDF definitions respectively. 
Prevalence of MS was higher in women using ATP III criteria (men 
17.1%, women 19.4%) and IDF criteria (men 23.1%, women 28.2%); but 
it was higher in men by WHO criteria (men 27.3%, women 19.7%). The 
prevalence of MS increased with age until the age of 69years and 
decreased thereafter based on all three criteria.99 
4. The age-adjusted prevalence of MS based on ATP III criteria in Jaipur 
(urban north Indian population) was 24.9%.100 
5. In a study conducted in the intracountry  migrant population that 
resides in urban slums, the prevalence of insulin resistance was 22.5-
26%.49 
38.78% patients with chronic CAD and 54.69% patients with ACS had 
metabolic syndrome. There is no significant difference in the prevalence of 
metabolic syndrome between males and females and between chronic CAD 
and ACS. 
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Since there was inadequate representation of the social classes, 
especially, class IV and V, social classes were excluded from analysis. 
My study concentrates on CAD patients living below poverty line and 
in this study prevalence of MS and its individual metabolic components, i.e., 
central obesity, hypertension, diabetes or IFG, hypertriglyceridemia and low 
HDL, were all found to be high compared to various studies conducted in 
India, but all of them have been conducted in community which include 
subjects with and without CAD. Relation between MS and CVD risk has been 
explained unequivocally in different studies.60-63 Conversely, there must be an 
increased prevalence of MS and its individual metabolic components in 
patients with coronary artery disease as compared to its prevalence in general 
population in the community. The result of my study confirms this fact. 
Prevalence of central obesity and hypertension were significantly 
higher in patients with ACS as compared to patients with chronic CAD. Thus 
presence of these risk factors means more severe disease to a patient with 
CAD. This finding not observed in hypertriglyceridemia, low HDL, diabetes 
and IFG. Interestingly, it was observed that central obesity, 
hypertriglyceridemia, diabetes and IFG and metabolic syndrome form a 
significant “U” shaped distribution in age groups. The proximal limb of this U 
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is formed by patients with premature coronary artery disease (age<40). This 
finding not observed on case of hypertension and low HDL. 
Hence clustering of these metabolic risk factors result in the onset of 
CAD earlier in these patients. Asian Indians have an earlier and more severe 
course of CHD compared to other ethnic groups.102A striking predisposition to 
premature coronary artery disease and early myocardial infarction has been 
observed among Asian Indians.1, 102 The mean age of an Asian Indian patient 
suffering a myocardial infarction is only 50 years.25% of all MIs in this population 
occur under the age of 40 years.89 Increased prevalence of metabolic syndrome and 
related  risk factors could explain these facts that are observed in above mentioned 
studies. 
  It is not clear why subjects who are generally manual labourers hence 
physically active, poor and cannot afford costly products of food industry should 
develop these clusters of metabolic risk factors. A simple explanation could be 
marked changes in their diets and lifestyle. Some data suggest that diets presently 
consumed by them were highly imbalanced. Specifically, the dietary consumptions 
of saturated fat and cholesterol were high and fiber and antioxidants were low.49 
Globalization and urbanization definitely has made an impact in their food habits, 
nutrition and physical activity. According to the “genetically unknown foods” 
hypothesis, adopting western dietary habits with a high fat and sucrose intake 
could lead to an epidemic of the IRS.103 Maladaptation, ‘stress response’ causing 
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hypothalamic pituitary activation, increased smoking and alcohol drinking may be 
additional contributory factors. Moreover we Indians form a special “Asian Indian 
phenotype”. 
Another explanation would be that urban poor living below poverty line due 
to inadequate nutrition especially during antenatal period leading to fetal 
immaturity thus acquiring thrifty phenotype that leads to increased risk of acquiring 
obesity and insulin resistance at an earlier age. 
Studies on the relationship of birth weight with insulin resistance 
syndrome variables in Indian children revealed that a lower birth weight is 
associated with insulin resistance.104 It has been hypothesized that lower birth 
weight followed by increased obesity could lead to IRS during adulthood.104 
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Conclusion 
The result of present study suggests that in urban patients who live 
below poverty line with symptomatic coronary artery disease there in 
increased prevalence of metabolic syndrome, central obesity, hyperglycemia, 
hypertension and dyslipidemia. The higher prevalence particularly noticeable 
in those with the premature coronary artery disease and that might have 
resulted in earlier onset of CAD in them. Moreover presence of central obesity 
and other risk factors might lead to more severe CAD, i.e., acute coronary 
syndrome.  
 It is assumed that adapting unhealthy life styles such as sedentary 
work, rich calory and imbalanced diet, malnutrition among antenatal mothers 
might be the cause for this occurrence.  
Coronary artery disease and its management pose a significant 
economical challenge and these patients who poor may not be able to meet the 
challenge, resulting in higher mortality and morbidity. Metabolic syndrome 
which is the emerging as a major risk factor for coronary artery disease in rich 
and poor further complicates the situation for these patients. So prevention of 
metabolic syndrome is better than cure for metabolic syndrome in these 
patients. 
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There is an urgent need to explore nutrition and physical activity and their 
role in the prevention and treatment of disorders directly or indirectly related to the 
metabolic syndrome.  It is possible that by diet, exercise, changes in lifestyle, 
and most impotantly by education the prevalence of metabolic syndrome and 
hence prevalence of coronary artery disease can be reduced and such a 
preventive strategy is urgent need of the hour for our country which is facing 
a twin epidemic of diabetes and coronary artery disease. 
This study identifies a class of society, which is in urgent need of such 
preventive measure. 
Prevention of MS 
 Intensive efforts should be made to make them aware that they are at more 
risk for development of type 2 diabetes and CAD. 
 Preventive measures should be particularly vigorous for those with the family 
history of type 2 diabetes and premature CAD. 
 Overweight individuals and those with abdominal obesity should be actively 
managed to lose weight by life style measures. 
 Detection of one component of metabolic syndrome should prompt the search 
of other components and its management. 
 Adequate nutrition during the intrauterine period should be given to prevent 
early life adverse events, which may promote insulin resistance in adulthood. 
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Early identification and treatment of metabolic syndrome and other metabolic 
risk factors goes long way in preventing coronary artery disease in these patients. 
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Limitations 
1. Due to inadequate representation from class IV and V of modified Prasad’s 
classification, the effect of social class in metabolic risk factors could not be 
studied. 
2. Sample size was 113. This might have resulted in type 2 error in the study due 
to small sample size. 
 
 
 
 
 
 
 
 
 
 
 
71 
 
Bibliography 
1. Balarajan R. Ethnic differences in mortality from ischemic heart disease and 
cerebrovascular disease in England and Wales. BMJ 1991; 302: 560-4 
2. Mckeigue PM, Miller GJ, Marmot MG. Coronary heart disease in South 
Asians overseas: a review. J Clin Epidemiol 1989; 42: 597-609. 
3. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, 
and cardiovascular disease between ethnic groups in Canada: the Study of 
Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000; 356: 279-
84. 
4. World Health Organization. The world health report 2002: reducing risks, and 
promoting healthy live. Geneva: WHO; 2002.   
5. Gupta R, Gupta VP, Sarna M, et al. Prevalence of coronary heart disease and 
risk factors in an urban Indian population: Jaipur Heart Watch-2. Indian 
Heart J 2002; 54: 59-66. 
6.  Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, 
estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 
1047-53. 
7. Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: 
visceral obesity and related comorbidity in Joannes Baptista Morgagni’s ‘De 
Sedibus et Causis Morborum per Anatomen Indagata’. Int J Obes Relat Metab 
Disord 2003; 27: 534-5. 
72 
 
8. Raeven GM. Banting lecture 1988: role of resistance in human disease. 
Diabetes 1988; 37: 1595-607. 
9. Joshi SR. Identification and Diagnostic Criteria of Insulin Resistance and 
Metabolic Syndrome. In: Joshi SR (Ed.) Primer of Insulin Resistance. 1st Ed. 
Asian Health Care, Mumbai 2003; 1: 29-32. 
10. Balkau B, Charles MA. Comment on the provisional report from the WHO 
Consultation. European Group for the study of Insulin Resistance (EGIR). 
Diabet Med 1999; 16(5): 442-443 
11. The IDF consensus worldwide definition of the metabolic syndrome. 
Available at 
http://www.idf.org/webdata/docs/IDF_Metasyndrome_defition.pdf. 
12. Executive summary of the Third Report of the National Cholesterol Education 
Programme (NCEP) Expert Panel on Detection, Evaluation and Treatment of 
High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA 2001; 
285: 2486-97. 
13. World Health Organization. Definition, Diagnosis and Classification of 
Diabetes Mellitus and its Complications. Part I: Diagnosis and Classification 
of Diabetes Mellitus. Report of a WHO Consultation. Geneva: World Health 
Organization, 1999, WHO/NCD/NCS/99.2. 
14. Vimaleswaran KS, Radha V, Anjana M, et al. Effects of polymorphisms in the 
PPARGC1A gene on body fat in Asian Indians. Int J Obes (Lond) 2006; 30: 
884-91 
73 
 
15. Witchel SF, DeFranco DB. Mechanisms of Disease: regulation of 
glucocorticoid and receptor levels—impact on the metabolic syndrome. Nat 
Clin Pract Endocrinol Metab 2006; 2: 621–631  
16. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships 
of generalized and regional adiposity to insulin sensitivity in men. J Clin 
Invest 1995; 96(1): 88-98. 
17. Guerre-Millo M. Adipose tissue harmones. J Endocrinol Invest 2002; 25(10): 
855-61. 
18. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue 
releases interleukin-6, but not tumour necrosis factor-alpha, in vivo. J Clin 
Endocrinol Metab 1997; 82: 4196-4200. 
19. Ritchie DG. Interleukin-6 stimulates hepatic glucose release from prelabeled 
glycogen pools. Am J Physiol 1990; 258: E57-64. 
20. Stouthard JM, Ramijn JA, Van der Poll T, et al. Endocrinologic and metabolic 
effects of interleukin-6 in humans. Am J Physiol 1995; 268: E813-E819.  
21. Grossi SG. Treatment of periodontal disease and control of diabetes: an 
assessment of the evidence and need for future research. Ann Periodontol 
2001; 6: 138-45. 
22. Jialal I, Devaraj S, Venugopal SK. Oxidative stress, inflammation, and diabetic 
vasculopathies: the role of alpha tocopherol therapy. Free Radic Res 2002; 36:  
1331-6 
74 
 
23. Muller S, Martin S, Koenig W, et al.  Impaired glucose tolarence is associated 
with increased serum concentration of inerleukin-6 and co-regulated acute-
phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45: 805-
12. 
24. van de Re MA, Huisman MV, Princen HM, Meinders AE, Kluft C: DALI-
study group. Strong disease of high sensitivity C-reactive protein with high-
dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 
2003; 166: 129-35. 
25. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other 
markers of inflammation in the prediction of cardiovascular disease in 
women. N Engl J Med 2002; 342: 836-43. 
26. Nappo F, Esposito K, Cioffi M, et al. Postprandial endothelial activation in 
healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate 
meals. J Am Coll Cardiol 2002; 39: 1145-50 
27. Misra A, Vikram NK. Clinical and pathophysiological consequences of 
abdominal adiposity and abdominal adipose tissue depots. Nutrition 2003; 19: 
457-66. 
28. Raeven GM. A syndrome of resistance to insulin stimulated uptake 
(Syndrome X). Definitions and implications. Cardiovasc Risk Factors 1993; 3: 
2-11. 
75 
 
29. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-
abdominal fat accumulation to the impairment of glucose and lipid 
metabolism in human obesity. Metabolism 1987; 36: 54-9. 
30. Despres JP, Moorjani S, Ferland M, et al. Role of deep abdominal fat in the 
association between regional adipose tissue distribution and glucose tolerance 
in obese women. Diabetes 1989; 38: 304-9. 
31. Pouliot MC, Despres JP, Nadeau A, et al. Visceral obesity in men. 
Associations with glucose tolerance, plasma insulin and lipoprotein levels. 
Diabetes 1992; 41: 826-34. 
32. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 
diabetes mellitus. Am J Med 2003 Dec 8; 115 Suppl 8A:24S-28S 
33. Robins SJ, Rubins HB, Faas FH et al. Insulin resistance and cardiovascular 
events with low HDL cholesterol. The Veterans Affairs HDL Intervention 
Trial (VA-HIT). Diabetes Care 2003; 26(5): 1513 
34. Steinmetz A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in 
the metabolic syndrome. Exp Clin Endocrinol Diabetes 2001: 109: S548-59 
35. Robins SJ, Collins D, Wittes JT et al. Relation of Gemfibrozil treatment and 
lipid levels with major coronary events. JAMA 2001; 285: 1585-91 
36. Shankar P, Sundarka M. Metabolic Syndrome: Its Pathogenesis and 
Management. JIACM 2003; 4(4): 275-81 
37. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in 
obesity. J Endocrinol Invest 2002; 25(10): 899-904. 
76 
 
38. Miller GJ. Lipoprotein and haemostatic system in atherothrombotic disorders. 
Baillieres Clin Hematol 1994; 7(3): 713-32 
39. Selwyn AP. Prothrombotic and antithrombotic pathways in acute coronary 
syndrome. Am J Cardiol  2003; 91(12A): 3H-11H 
40. Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917): 868-74. 
41. Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, et al. C-
reactive protein activates the nuclear factor-κB signal transduction pathway in 
saphenous vein endothelial cells: implications for atherosclerosis and 
restenosis. J Thorac Cardiovasc Surg 2003; 126(6): 1886-91 
42. Ridker PM. Clinical application of C-reactive protein for cardiovascular 
disease detection and prevention. Circulation 2003; 107(3): 363-9 
43. Pradhan AD, Manson JE, Rafai N, Buring JE, Ridker PM. C-reactive protein, 
interleukin-6, and the risk of developing type 2 diabetes mellitus. JAMA 2001; 
286(3): 327-34. 
44. Ridker PM, Buring JE, Cook NR, Rafai N. C-reactive protein, the metabolic 
syndrome, and risk of incident of cardiovascular events: an 8-years follow-up 
of 14719 initially healthy American women. Circulation 2003; 107(3): 391-7 
45. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S.  The metabolically 
obese, normal-weight individuals revisited. Diabetes 1998; 47: 699-713. 
46. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by 
"progress"? Am  J  Hum  Genet  1962;14: 353–62 
77 
 
47. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the 
thrifty phenotype hypothesis. Diabetologia 1992; 35: 595-601. 
48. Barker DJ, Eriksson JG, Forsen T, Osmond C. Fetal origins of adult disease: 
strength of effects and biological basis. Int J Epidemiolol 2002; 31: 1235-9. 
49. Misra A, Vikram NK. Insulin resistance syndrome (metabolic syndrome) and 
Asian Indians. Current Science 2002; 83: 12:1483- 97. 
50. Ramachandran A, Snehalatha C, Viswanathan V, Viswanathan M, Haffner 
SM. Risk of noninsulin dependent diabetes mellitus conferred by obesity and 
central obesity in different ethnic groups: a comparative analysis between 
Asian Indians, Mexican Americans and Whites. Diabetes Res Clin Pract. 1997; 
36: 121-5. 
51. Chandalia M, Abate N, Garg A, Stray-Gundersen J, Grundy SM. Relationship 
between generalized and upper body obesity to insulin resistance in Asian 
Indian men. J Clin Endocrinol Metab. 1999; 84: 2329-35. 
52. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin 
resistance in healthy Asian Indians and Caucasians. J Clin Endicrinol Metab. 
2001; 86: 5366-71. 
53. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, 
visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin 
Endocrinol Metab. 1999; 84: 137-44 
54. Kamath SK, Hussain EA, Amin D, Mortillaro E, West B, Peterson CT, Aryee F, 
Murillo G, Alekel DL. Cardiovascular disease risk factors in 2 distinct ethnic 
78 
 
groups; Indian and Pakistani compared with American premenopausal 
women. Am J Clin Nutr 1999; 69: 621-31. 
55. Chowdhury B, Lantz H, Sjostrom L. Computed tomography-determined body 
composition in relation to cardiovascular risk factors in Indian and matched 
Swedish males. Metabolism 1996; 45; 634-44. 
56. Mohan V, Deepa R, Velmurugan K, Premalatha G. Association of C-reactive 
protein with body fat, diabetes and coronary artery in Asian Indians: the 
Chennai Urban Rural Epidemiology Study (CURES-6). Diabet Med 2005; 22: 
863-70. 
57. Misra A, Sinha S, Kumar M, Jagannathan NR, Pandey RM. Proton magnetic  
resonance spectroscopy study of soleus muscle in non-obese healthy and type 
2 diabetic Asian northern Indian males: High intramyocellular lipid content 
correlates with excess body fat and abdominal obesity. Diabet Med 2003; 20: 
361-7 
58. Farouhi NG, Jenkinson G, Thomas EL, Mullick S, Mierisova S, Bhonsle U, et 
al. Relation of triglyceride stores in skeletal muscle cells to central obesity and 
insulin sensitivity in European and South Asian men. Diabetologia 1999; 42: 
932-5 
59. WHO Expert consultation. Appropriate body-mass index for Asian 
populations and its implications for policy and intervention strategies. Lancet 
2004; 363: 157-63. 
79 
 
60. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does 
the metabolic syndrome improve identification of individuals at risk of type 2 
diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676-81.  
61. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, 
Tuomilehto J, Salonen JT: The metabolic syndrome and total and 
cardiovascular disease mortality in middle aged men. JAMA 2002; 288: 2709-
16. 
62. Hu G,  Qiao Q, Tuomilehto J, Balkau B, Borch-Johnson K, Pyorala K. 
DECODE Study Group, Prevalence of the metabolic syndrome and its relation 
to all-cause and cardiovascular mortality  in nondiabetic European men and 
women. Arch Intern Med 2004; 164: 1066-76. 
63. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, Isles C, 
Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with 
and without C-reactive protein as a predictor of coronary heart disease and 
diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 
108: 414-9. 
64. Lindström J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention 
Study (DPS): Lifestyle intervention and 3-year results on diet and physical 
activity. Diabetes Care 2003; 26: 3230-6. 
65. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of Type 2 diabetes 
mellitus by changes in lifestyle among subjects with impaired glucose 
tolerance. N Engl J Med 2001; 344: 1343-50. 
80 
 
66. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection 
Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a 
randomized placebo-controlled trial. Lancet 2003; 361: 2005-16. 
67. Haffner SM, Alexander CM, Cook TJ et al. Reduced coronary events in 
simvastatin treated patients with coronary heart disease and diabetes mellitus 
or impaired fasting glucose levels: subgroup analysis on the Scandinavian 
Simvastatin Survival Study. Arch Intern Med 1999; 159(22): 2661-7. 
68. Goldberg RB, Mellies MJ, Sacks FM et al. for the CARE investigators. 
Cardiovascular events and their reduction with pravastatin in diabetic and 
glucose-intolerant myocardial infarction survivors with average cholesterol 
levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) 
trial. Circulation 1998; 98: 2513-9. 
69. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National 
Committee on prevention, detection, evaluation, and treatment of high blood 
pressure. Hypertension 2003; 42(6): 1206-52. 
70. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of 
type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 
346(6): 393-403. 
71. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic beta-cell 
function and prevention of type 2 diabetes by pharmacological treatment of 
insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-803. 
81 
 
72. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 
diabetes in patients with impaired glucose tolerance and insulin resistance. 
Diabetes Obes Metab 2004; 6: 280-5. 
73. Chiasson JL, Josse RG, Gomis R et al. STOP-NIDDM Trial Research Group. 
Acarbose treatment and the risk of cardiovascular disease and hypertension 
in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 
2003 Jul23; 290(4): 486-94. 
74. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the Prevention of 
Diabetes in Obese Subjects (XENDOS) Study. A randomized study of orlistat 
as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese 
patients. Diabetes Care 2004; 27: 155-61. 
75. Gibbons RJ, Chatterjee K, Daley J, et al., American College of 
Cardiology/American Heart Association, American College of Physicians-
American Society of Internal Medicine (ACC/AHA/ACP-ASIM) guidelines for 
management of patients with chronic stable angina:  A report of the 
ACC/AHA Task Force on Practice Guidelines (Committee on the 
Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 2002; 
41: 160-168. 
76. Diamond GA, Staniloff HM, Forrester JS, et al. Computer-assisted diagnosis 
in the noninvasive evaluation of patients with suspected coronary disease. J 
Am Coll Cardiol 1983; 1: 444-455. 
77. Duprez DA: Angina in elderly. Eur Heart J 17(Suppl G):8-13, 1996. 
82 
 
78. Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA guideline update for 
the management of patients with unstable angina and non-ST segment 
elevation myocardial infarction – 2002: Summary article: A report of the 
American College of Cardiology/ American Heart Association Task Force on 
Practice Guidelines (Committee on the Management of Patients with Unstable 
Angina). Circulation 106: 1893, 2002. 
79. Braunwald E. Unstable angina: A classification. Circulation 1989; 80: 410-414. 
80. Campeau L: Grading of angina pectoris (letter). Circulation 54: 522-523, 1976. 
81. Hamm CW, Braunwald E: A classification of unstable angina - Revisited. 
Circulation 102: 118, 2000 
82. Pedoe-Tunstall H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and 
coronary deaths in the World Health Organization MONICA Project. 
Circulation 1994; 90: 583-612 
83. Statistical Outlines of India (1995-96), TATA Services Ltd. Department of 
economics and Statistics.  
84. Prasad B.G.; changes proposed in the social classification of Indian Families. J 
Indian Med Assoc 1970: 55: 198-199.  
85. Prasad D.G.; changes proposed in the social classification of Indian Families. J 
Indian Med Assoc 1970: 55: 198-199.  
86. Kumar P. Social Classification-need for constant updating Indian Journal of 
Community Medicine 1993: Vol XVIII,No.2: 60-61 
83 
 
87. Central Statistical Organization, Ministry of Statistics and Programme 
Implementation, Government of India.  Consumer Price Index for  Urban  
Non-Manual Employees for January, 2007; 2007 Feb 26.  Available at:  
http://mospi.nic.in/mospi_cpi.htm   
88. Last, John M.ed. (1983). A Dictionary of epidemiology, A Handbook 
sponsored by the IEA, Oxford Univ. Press. 
89. Siwach SB, Singh H, Sharma D, Katyal VK. Profile of young acute 
myocardial infarction in Harayana. J Assoc Physicians India 1998; 46: 424-6. 
90. Gopalan C. Obesity in the urban middle class. NFI Bull 1998; 19: 1-4. 
91. Mohan V, Shanthi Rani S, Deepa R, et al. Intra-urban differences in the 
prevalence of the metabolic syndrome in southern India-The Chennai Urban 
Population Study (CUPS -4). Diabet Med 2001; 18: 280-7. 
92. Shanthi Rani CS, Rema M, Deepa R, Premalatha G, Ravikumar R, Anjana 
Mohan, Sastry NG, Ramu M, Saroja R, Kayalvizhy G, Mohan V. The Chennai 
Urban Population Study (CUPS)-Methodological Details (CUPS Paper No.1). 
Int J Diab Dev Countries 1999; 19: 149-57. 
93. Whelton PK. Blood pressure in adults and elderly In: Handbook Of 
Hypertension, vol.6: Epidemiology of Hypertension, Bulpitt CJ (Ed.) 
Amsterdam: Elsevier, 1985; 51-69 
94. Roeters van Lennep, Jeanine E. Risk factors for coronary heart disease: 
implications of gender. Cardiovasc Res: 2002; 53: 538-49. 
84 
 
95. Ramachandran A, Viswanathan M, Mohan V. Epidemiology of NIDDM in 
Indians. J Assoc Physicians India 1993; 41: 1-4. 
96. Ramachandran A, Jali MV, Mohan V, et al. High prevalence of diabetes in an 
urban population in south India. BMJ 1988; 297: 587-90. 
97. Ward AMV, Fall CHD, Stain CE, et al. Cortisol and metabolic syndrome in 
south Asians. Clin Endocrinol (Oxf) 2003; 58: 500-5. 
98. Ramachandran A, Snehalatha C, Satyavani K, et al. Metabolic syndrome in 
urban Asian Indian adults: a population study using modified ATP III 
criteria. Diabetes Res Clin Pract 2003; 60: 199-204. 
99. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic 
syndrome using WHO, ATP III and IDF definitions in Asian Indians: The 
Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res 
Rev 2006 Jun 5: (E pub ahead of print). 
100. Gupta R, Deedwania PC, Gupta A, et al. Prevalence of metabolic syndrome 
in an Indian urban population. Int J Cardiol 2004; 97: 257-61. 
101. Wannamathee S Goya. Commentary: prevention of coronary artery disease 
in South Asian-containing the physical inactivity epidemic. Int J Epidemiol 
2004; 33:   1-2. 
102. Ranjth N, Verho NK, Verho M, winkelmann BR. Acute myocardial 
infarction in a young South African Indian-based population: patient 
characteristics in admission and gender-specific risk factor prevalence. Curr 
Med Res Opin 2002; 18: 242-8. 
85 
 
103. Baschetti R. Diabetes epidemic in newly westernized populations: is it due 
to thrifty genes or to genetically unknown foods? J R Soc Med 1998; 91: 622-5 
104. Yajnik CS. The insulin resistance epidemic in India: fetal origins, later 
lifestyle or both?  Nutr Rev 2001 ; 59: 1-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proforma  
Name                                                                                 Hospital No. 
Age                                                                                    Date of admission 
Sex                                                                                     Date of discharge 
Address 
Socio‐economic Status 
Occupation 
Income (monthly) 
Modified Prasad’s Classification 
Diagnosing Coronary Artery Disease 
(I) History 
Chest pain 
Site 
Character  
Onset (new i.e. with in 1 month/old) 
Duration (<20min/ 20‐30min/ >30 min) 
Progression in past 60 days (crescendo pattern) 
Frequency 
Aggravating factor 
Rest 
• Angina at rest within past 1 month but not within preceding 48 h 
• Angina at rest within 48 h 
S/L nitroglycerine 
CCA Class 
Angina equivalents  
Dyspnea, fatigue, faintness and eructation 
Pregnancy (in females of reproductive age) 
Drug abuse 
Past History 
MI within 2 weeks 
MI after 2 weeks 
Thrombolysis  
IHD and Rx 
Examination 
Pulse                /min 
BP                 mmHg 
RR                  /min 
Temperature                  degree Fahrenheit 
SaO2              % 
JVP                cm 
Pallor 
Thyroidomegaly 
Edema 
Height 
BMI 
CVS  
RS 
Abdomen 
CNS 
Hemoglobin 
Hematocrit      
   
 (II) Electrocardiogram 
 
 
 
 
First ECG 
 
 
ECG after 24 hours 
 
 
 
 
leads 
 
 
 
Myocardial localization 
 
 
 
 
T inversion  
 
 
 
 
 
 
 
 
 
 
 
ST elevation  
 
 
 
 
 
 
 
 
 
ST depression 
 
 
 
 
 
 
 
 
 
Q wave  
 
 
 
 
 
 
 
 
 
LBBB 
     
               
(III) Creatinine Kinase ‐ MB 
 
At  presentation 
 
24 hour later 
   
                   Secondary causes  
• Fever  
• Thyrotoxicosis 
• Tachycardia 
• Hypertension 
• Aortic Stenosis 
• High Output State 
• Pregnancy 
• Drugs: Cocaine, Amphetamine 
• Anemia 
• Hypoxemia (pneumonia, CCF etc) 
• Hypotension 
Diagnosis 
1. Chronic coronary artery disease  
• Stable angina 
• Old MI 
2. Acute coronary Syndrome 
• Unstable angina – Braunwald Class. 
• NSTEMI. 
• ST elevation MI. 
 
DIAGNOSING METABOLIC SYNDROME 
Waist Circumference 
First reading  Second reading  Average 
 
 
 
 
 
 
Blood pressure (in mm Hg) 
 
Day 1 
 
Day 2 
 
Average 
     
Treatment of previously diagnosed hypertension 
Fasting blood sugar (in mg per dL) 
 
Day 1 
 
Day 2 
 
Day 3 
 
Average 
       
Previously diagnosed type 2 diabetes 
 Fasting lipid profile 
 
TGL 
 
LDL 
 
HDL 
 
TC 
 
VLDL 
LDL/HDL 
Ratio 
           
Specific treatment for this lipid abnormality 
 
Diagnosis Metabolic syndrome 
 
 
Abbreviations 
ACS    Æ  Acute Coronary Syndrome 
ADA    Æ  American Diabetic Association 
AICPI     Æ  All India Consumer Price Index 
Apo B   Æ  Apo lipoprotein B 
ATP III    Æ  Adult Treatment Panel III   
BMI    Æ  Body Mass Index 
CAD    Æ   Coronary Artery Disease 
CCS     Æ  Canadian Cardiovascular Society  
CHD    Æ  Coronary Heart Disease 
CHAOS  Æ  Coronary  artery  disease,  High  Blood  Pressure,  Adult  Onset        
Diabetes (type 2), Obesity, and Stroke 
CI    Æ  Confidence Interval 
CK‐MB    Æ  Creatine Kinase – MB 
CPI    Æ  Consumer Price Index 
CRP    Æ  C ‐ reactive protein 
CUPS    Æ  Chennai Urban Population Study 
CVD    Æ  Cardiovascular disease 
DBP    Æ  Diastolic Blood Pressure 
DPP     Æ  Diabetes Prevention Program 
ECG    Æ  Electrocardiogram 
EGIR    Æ  European Group for the study of Insulin Resistance 
FBS    Æ  Fasting Blood Sugar 
HDL    Æ  High Density Lipoprotein 
IDF    Æ   International Diabetic Federation 
IFG    Æ  Impaired Fasting Glucose 
IGT     Æ  Impaired Glucose Tolerance 
IL‐6    Æ   Interleukin‐6 
IMCL    Æ  Intramyocellular lipids 
JNC 7    Æ   Joint National Committee 
KMC     Æ  Govt. Kilpauk Medical College 
LDL    Æ   Low density Lipoprotein 
MS     Æ  Metabolic Syndrome 
MI    Æ   Myocardial Infarction 
NCEP   Æ  National Cholesterol Education Program 
NEFA   Æ  Non‐esterified Fatty Acid 
NSTEMI  Æ  Non‐ST elevation MI 
PAI‐I     Æ  Plasminogen Activator Inhibitor‐ I 
PPAR γ 2  Æ  Peroxisome proliferator‐activated receptor γ 2 
PPARGC1A  Æ  Peroxisome proliferator‐activated receptor γ co‐activator‐1 α 
SBP    Æ  Systolic Blood Pressure 
STEMI    Æ  ST elevation MI 
TG    Æ  Triglyceride 
TNF‐α  Æ  Tumour Necrosis Factor‐ α 
UCP‐1  Æ  Uncoupling Protein‐1 
UA    Æ  Unstable Angina 
VA‐HIT  Æ  Veterans Affairs High‐Density Lipoprotein Intervention Trial 
WHO    Æ  World Health Organization 
WOSCOPS  Æ  West of Scotland Coronary Prevention Study 
Abbreviations in Master Chart 
SN    Æ   Serial Number 
HospNo  Æ  Hospital Number 
SocClass  Æ  Social Class 
ChrCAD  Æ   Chronic Coronary Artery Disease 
ACS    Æ  Acute Coronary Syndrome 
STEMI  Æ  ST elevation myocardial infarction 
NSTEMI  Æ  non‐ ST elevation myocardial infarction 
UA    Æ  Unstable Angina 
Waist   Æ  Waist Circumference 
SBP    Æ   Systolic Blood Pressure 
DBP    Æ   Diastolic Blood Pressure 
c/oHTN  Æ  known case of hypertension 
FBS    Æ  Fasting Blood Sugar 
c/oDM  Æ  known case of diabetes mellitus 
TG    Æ  Triglyceride 
HDL    Æ  High Density Lipoprotein 
c/oDyslipid Æ  known case of Dyslipidemia 
MS    Æ  Metabolic Syndrome 
M    Æ  Male 
F    Æ   Female 
